CClinicalTrials.gg
TerminatedNCT01172197Updated May 9, 2018Results posted

Comparison of Levobupivacaine and Ropivacaine for Femoral Neural Block

A Phase 4 interventional study of Levobupivacaine and Ropivacaine in Pain and Arthroplasty, Replacement, Knee, sponsored by NHS Tayside. Terminated. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-05-09.

Sponsored by NHS Tayside · Phase 4, Interventional, and Treatment

Why this study was terminated
Terminated prior to its planned completion as anticipated by the protocol).
Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The anaesthetic management of patients undergoing total knee replacement is still not standardised. Epidural analgesia is common, but is associated with bilateral lower limb motor block and limited mobilisation. Spinal anaesthesia with intrathecal morphine provides good pain relief, but only for 12 to 16 hours, and is often associated with nausea and vomiting. Combined single injection femoral / sciatic blocks give good pain relief, but for a variable length of time (between 12 and 24 hours).

In contrast, continuous femoral perineural infusion of local anaesthetic provides very good pain relief for several days. Pain relief is maintained by a constant infusion of local anaesthetic using an elastomeric ball. The investigators overriding aim is to develop a local anaesthetic regimen which offers complete pain relief for at least 48 hours, yet allows full mobilisation within 24 hours Given that ropivacaine may offer a more advantageous pharmacological profile (less lipid solubility) compared to levobupivacaine, the investigators feel it is pertinent to investigate the capacity of ropivacaine to prevent pain relief after surgery. Thus, the investigators aim in this study is to compare the median effective dose of levobupivacaine with the of ropivacaine for preventive pain relief after total knee replacement. Further, calculation of the equipotent median effective dose's of each local anaesthetic allied to objective measurement of quadriceps motor block using an electromyogram will allow us to determine the sensory - motor split of each local anaesthetic.

Read the detailed description

Primary objective The primary aim of this study is to measure the molar of levobupivacaine and the molar median effective dose of ropivacaine when administered as a femoral perineural infusion to prevent pain 30 hours after total knee replacement Secondary objectives

To assess the:

Degree of postoperative pain, need for rescue analgesia,side effect profile of both groups, self-efficacy, expectancy, quality of life / health economics Type of study: Prospective single blind randomised controlled trial Planned number of subjects: 48 Study duration: 24 months Randomisation procedures Following informed consent, participants will be randomised into two groups. All preparations for study will be coded so that participants have an equal chance of receiving one of the two local anesthetics. Randomisation will be carried out by computer program, and codes kept in pharmacy in a sealed envelope.

Protocol for patient management Preoperative - Anaesthetic room Antibiotics: augmentin 1.2 grams Sedation with Target Controlled Infusion of propofol at plasma level of 0.5 micrograms per millilitre (μg.ml-1) Spinal anaesthesia with 3.2 ml hypobaric "plain" bupivacaine 0.5% and intrathecal morphine 0.1 mg All regional nerve blocks performed under ultrasound control Femoral block: 15 ml 0.3% levobupivacaine or ropivacaineFemoral perineural catheter inserted by Anaesthetist 5cm in a cranial direction Sciatic block: single injection 12 ml 0.5% levobupivacaine or ropivacaine Obturator block: single injection 6 ml 0.5% levobupivacaine or ropivacaine

Postoperative 8 hour anaesthetic observation

Determine median effective dose of levobupivacaine and ropivacaine for anaesthesia 8 hours after insertion of spinal needle, resolution of spinal anaesthesia confirmed and verbal rating pain score of knee bending recorded. Clinical measurement and subsequent patient dosing is as follows:

  1. "Anaesthetic success": verbal rating pain score = 0: Next patient receives 10 microMolar (μM) less of levobupivacaine or 10μM ropivacaine.
  2. "Anaesthetic failure": verbal rating pain score ≥ 1. Resolved by rescue analgesia of 15ml, 150μM levobupivacaine (5.8ml, 0.75%) or 15ml, 150μM ropivacaine (6.2ml, 0.75%).Next patient receives 10μM more of levobupivacaine or 10μM ropivacaine.
  3. Technical failure: verbal rating pain score ≥ 1 Not resolved by rescue analgesia of 15ml, 150μM levobupivacaine (5.8ml, 0.75%) or 15ml, 150μM ropivacaine (6.2ml, 0.75%.Next patient receives same mass levobupivacaine or ropivacaine.

After the 8 hour assessment, all patients (excluding technical failures but including "anaesthetic failures") will start a femoral perineural infusion with levobupivacaine or ropivacaine at a rate of 10ml h-1 and concentration of 1(microMolar per millilitre) μM.ml-1 (400μM in 400ml elastomeric ball) for 48 hours.Patients classed as "technical failure" will have a femoral perineural catheter reinserted.

Postoperative 30 hour (±2hour) anaesthetic observation

The postoperative 30 hour anaesthetic observation will only be performed on the "anaesthetic successes" from the 8 hour observation. The median effective dose of levobupivacaine and ropivacaine for analgesia will be determined by choosing an end point of verbal rating pain score 0 at 30h after the start of spinal anaesthesia. Patients will divide into three groups:

  1. "Successful pain relief" verbal rating pain score = 0 Next patient receives 10μM less of levobupivacaine or 10μM ropivacaine.
  2. "Unsuccessful pain relief" verbal rating pain score ≥ 1 resolved by rescue analgesia of 15ml, 50μM levobupivacaine (5.8ml, 0.25% + saline) or 15ml, 50μM ropivacaine (7.7ml, 0.20% + saline).Next patient receives 10μM more of levobupivacaine or 10μM ropivacaine.
  3. Technical failure: verbal rating pain score ≥ 1. Not resolved by rescue analgesia of 15ml, 50μM levobupivacaine (5.8ml, 0.25% + saline) or ml, 50μM ropivacaine (7.7ml, 0.20% + saline).

Rescue analgesia Rescue will be standardised: 15ml, 50μM levobupivacaine (5.8ml, 0.25% + saline) or 15ml, 50μM ropivacaine (7.7ml, 0.20% + saline). The number of rescue administrations will be counted.

.

02

Conditions studied

  • Pain
  • Arthroplasty, Replacement, Knee

Keywords

  • local anesthetic
  • levobupivacaine
  • ropivacaine
  • femoral perineural block
03

In context

Lead sponsor

NHS Tayside is the lead sponsor of 28 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All patients >18 years of age and non pregnant presenting for elective knee replacement

Exclusion criteria

Exclusion Criteria:

  • Signs of cardiac failure (3rd heart sound, lung crepitations)
  • Type I and type II diabetes
  • Abnormal cardiac arrhythmias
  • Hypovolaemia
  • Presence of seizures,
  • Dementia,
  • Depression
  • Encephalopathy,
  • Terminal illness with a life expectancy \< 3 months
  • Age \< 18 years
  • Pregnant
  • Coagulopathy
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Active comparator
    Ropivacaine

    Local anaesthetic bolus and infusion

    Drug: Levobupivacaine

  • Active comparator
    Levobupivacaine

    Local anaesthetic bolus and infusion

    Drug: Ropivacaine

Interventions

  • DrugLevobupivacaine

    Femoral bolus 150μM followed by femoral infusion 400μM

    Also known as: Chirocaine

  • DrugRopivacaine

    Bolus and infusion

    Also known as: Naropin

06

What researchers measure

Primary outcomes

  1. Pain

    Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion

    Time frame: 30 hours

07

Results

Posted May 9, 2018

Participant flow

Patients recruited on ward 24h before procedure. Patient information sheet sent to patients 3 weeks before operation

Participant flow — Overall Study
MilestoneRopivacaineLevobupivacaine
Started77
Completed77
Not completed00

Outcome measures

PrimaryPain

Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion

Time frame:
30 hours
Reported as:
Count of participants · Participants
Pain
ParticipantsRopivacaineLevobupivacaine
Pain77

Adverse events

Collected over 30h. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ropivacaine0/7 (0%)0/7 (0%)0/7 (0%)
Levobupivacaine0/7 (0%)0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)RopivacaineLevobupivacaineTotal
Median60 (53 to 70)64 (56 to 72)62 (53 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)RopivacaineLevobupivacaineTotal
Female325
Male459
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)RopivacaineLevobupivacaineTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)RopivacaineLevobupivacaineTotal
United Kingdom7714
08

Study locations

No study locations are listed for this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01172197
Lead sponsor
NHS Tayside
Responsible party
Sponsor
First posted
Jul 29, 2010
Start date
Jan 2009
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
May 9, 2018
Last update
May 9, 2018

Study contacts

Graeme A McLeod, MD FRCA
principal investigator · NHS Tayside

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion